Number of the records: 1

ipilimumab

SYS		d000074324
LBL		00000nx^^^2200181-^^45^^
005		20240119201521.0
100		$a 20180101asloy0103 ba0
152		$b mesh
250		$a ipilimumab $x AD $x AE $x AN $x BI $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PH $x PK $x PO $x RE $x TO $x TU $x UL $x UR $8 slo
300	1-	$a 2018(2012) $8 eng
330	1-	$a An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells. $8 eng
450		$a anti-CTLA-4 MAb ipilimumab $5 e $8 slo
450		$a MDX 010 $5 e $8 slo
450		$a MDX-CTLA-4 $5 e $8 slo
550		$3 sllk_un_auth*d060908 $Y CTLA-4 Antigen $5 F $a antigén CTLA-4
550		$3 sllk_un_auth*d060908 $Y CTLA-4 Antigen $5 B $a antigén CTLA-4
686		$a D12.776.124.486.485.114.224.060.798
686		$a D12.776.124.790.651.114.224.060.798
686		$a D12.776.377.715.548.114.224.200.798
750		$a Ipilimumab $8 eng
801	-0	$a SK $b BA006 $c 20180615
801	-2	$a SK $b BA006 $c 20180727
980		$x M

Number of the records: 1